The disclosure relates to compounds that are, e.g., PAP Associated Domain Containing 5 (PAPD5) inhibitors and methods of use thereof.

The present disclosure relates to an organic electroluminescent compound, and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to provide an organic electroluminescent device having improved driving voltage, lifetime properties, and/or power efficiency.

Disclosed by the present invention are a thienocyclic compound represented by formula (I), a pharmaceutically acceptable salt or a hydrate thereof, a composition containing the thienocyclic compound, and a preparation method therefor. Further disclosed by the present invention is an application of the thienocyclic compound as a prostaglandin EP4 receptor antagonist that is used for preventing and treating prostaglandin PGE2-mediated diseases, comprising malignant tumors, autoimmune diseases, inflammation, pain and osteoarthritis

##STR00001##

Disclosed by the present invention are a thienocyclic compound represented by formula (I), a pharmaceutically acceptable salt or a hydrate thereof, a composition containing the thienocyclic compound, and a preparation method therefor. Further disclosed by the present invention is an application of the thienocyclic compound as a prostaglandin EP4 receptor antagonist that is used for preventing and treating prostaglandin PGE2-mediated diseases, comprising malignant tumors, autoimmune diseases, inflammation, pain and osteoarthritis

##STR00001##

Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, an organic electroluminescent device having improved driving voltage, luminous efficiency, and/or lifespan characteristics can be provided.

The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.

The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent device having a low driving voltage and/or a high luminous efficiency and/or a long lifespan can be provided, by comprising an organic electroluminescent compound according to the present disclosure.

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent device having a low driving voltage and/or a high luminous efficiency and/or a long lifespan can be provided, by comprising an organic electroluminescent compound according to the present disclosure.